227-21 | A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

Overview

“A Phase III, Open-Label, Randomized Study of Atezolizumab and Tiragolumab Compared with Durvalumab in Patients with Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent Platinum-Based Chemoradiation (SKYSCRAPER-03)”

This is a Phase III, open-label, randomized, global, multicenter study designed to evaluate the efficacy and safety of atezolizumab in combination with tiragolumab compared with durvalumab administered to patients with locally-advanced, unresectable Stage III NSCLC who have not progressed following concurrent platinum based of CRT as consolidation therapy.